Found 326 clinical trials
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Phase II trial of nivolumab in 120 treatment nave patients with ccRCC.
- 82 views
- 25 Apr, 2021
- 12 locations
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
active to warrant further investigation in randomized phase II or III studies. Metastatic renal cell cancer (mRCC) patients with PD-1 expressing immune cells are more likely to have larger more
- 0 views
- 30 Mar, 2021
- 3 locations
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.
-squamous or squamous NSCLC, RCC, OC, or melanoma.
- 70 views
- 08 May, 2021
- 16 locations
NPC - AXEL Study : Axitinib-Avelumab
recurrent or metastatic NPC who failed at least first line chemotherapy. The combination of axitinib and avelumab has been studied in renal cell carcinoma (RCC). Based on the above promising and
- 0 views
- 14 May, 2021
- 1 location
Salvage Therapy With Sunitinib Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
sutent was approved to effective by two phase II trials in advanced renal cell carcinoma patients after failure of immunotherapies, and one phase III trial in treatment-naive advanced renal
- 2 views
- 08 Nov, 2020
- 1 location
Anesthesia and Cancer Study: Renal Cell Carcinoma
This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either
- 0 views
- 25 Jan, 2021
- 1 location
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1
- 0 views
- 19 Jun, 2021
- 5 locations
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer
- 0 views
- 23 Jan, 2021
- 1 location
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
activity for cabozantinib in patients with advanced renal cell carcinoma and metastatic castration-resistant prostate cancer (mCRPC). Furthermore, in preclinical models of urothelial carcinoma (UC) of the
- 46 views
- 26 Jan, 2021
- 12 locations
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
- 0 views
- 20 Jun, 2021
- 42 locations